Premium
Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist
Author(s) -
Fujimoto Yoshifumi,
Sasaki Tamito,
Tsuchida Akira,
Chayama Kazuaki
Publication year - 2001
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(01)02377-8
Subject(s) - angiotensin ii receptor type 1 , angiotensin ii , pancreatic cancer , receptor , antagonist , endocrinology , receptor antagonist , growth inhibition , angiotensin receptor , medicine , chemistry , renin–angiotensin system , cancer research , cancer , pharmacology , biology , cell growth , biochemistry , blood pressure
We investigated the expression of angiotensin II type 1 receptor (AT1) in pancreatic cancer. Both AT1 mRNA and protein were expressed in human pancreatic cancer tissues and cell lines. Binding assays showed that pancreatic cancer cells have specific binding sites for angiotensin II and that binding could be eliminated by treatment with a selective AT1 antagonist in a dose‐dependent fashion. Surprisingly, the growth of cancer cells was significantly suppressed by treatment with antagonist, also in a dose‐dependent manner. These observations suggest AT1 plays an important role in pancreatic cancer growth. Furthermore, ligand‐induced inhibition of AT1 may be a useful therapeutic strategy.